The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for revolutionary treatments and impressive returns is clear, the associated risks are also significant